Biodesix reported a breakout quarter to close 2025, delivering $28.8 million in Q4 revenue with 83% gross margins and, notably, its first-ever adjusted EBITDA positive quarter. Full-year revenue reached $88.5 million, up 24% year over year, with gross margin at 81%. The lung-focused diagnostics company guided 2026 revenue to $106–112 million, implying roughly 23% growth at the midpoint, and expects to maintain about 80% gross margin while progressing toward sustained profitability. The company also extended its senior secured term loan maturity to November 2028 and raised additional capital via an at-the-market program, bringing pro forma cash to $33.7 million.
The immediate strategic question is whether Biodesix has crossed from scale-up to scaling efficiently in a diagnostics market where payer scrutiny, regulatory tightening, and capital discipline are reshaping the field. Hitting adjusted EBITDA positivity, even for a single quarter, signals operating leverage is real: diagnostic test revenue grew 46% in Q4 to $25.1 million on 23% higher test volumes and improved average revenue per test, supported by broader payer coverage and stronger revenue cycle management. If sustained, that mix—more tests at higher realized prices with streamlined lab costs—changes the unit economics of lung nodule triage and treatment guidance.
This matters now because lung cancer screening is finally expanding in practice, not just on paper. As more CT scans uncover indeterminate nodules, clinicians and payers are searching for validated tools that reduce unnecessary invasive procedures without missing early cancers. Biodesix’s lung nodule risk assessment (Nodify Lung) and treatment guidance (iQLung) portfolio sits directly in that decision flow across pulmonology, radiology, and thoracic surgery. Rising average revenue per test suggests coverage is catching up to clinical utility claims, a positive signal for hospital systems and IDNs looking to standardize pathways, and for payers seeking to manage downstream costs. For patients, broader access to accurate triage could mean fewer avoidable biopsies and faster routes to the right therapy.
The growth in development services revenue—up 41% for the year to $9.3 million—also underscores a durable trend: biopharma’s appetite for external diagnostics expertise to enable trial enrichment, biomarker strategies, and post-market evidence. As pharma pipelines lean into precision oncology and decentralized data generation, diagnostics partners with high-throughput platforms, CLIA infrastructure, and operational know-how can become recurring revenue engines rather than episodic project shops. For BD teams, this is a signal that companion and complementary diagnostics models are evolving toward multi-test, multi-asset collaborations with embedded real-world evidence components.
Yet the competitive and policy context remains complex. Larger oncology diagnostics players are pushing into nodule risk and early detection from different angles, while hospital labs weigh in-house assays against send-out convenience and evidence packages. At the same time, evolving oversight of laboratory-developed tests will add compliance costs and could favor scaled operators with robust quality systems. Sustaining roughly 80% gross margins while navigating payer re-evaluations, coding dynamics, and potential changes in coverage frameworks will test commercial and market access execution as much as scientific differentiation.
The next milestone is not just more growth, but proof that clinical data can convert into durable, guideline-aligned adoption across community and academic settings—and that payer contracts can lock in improved economics at scale. If Biodesix can translate its Q4 inflection into multi-quarter operating momentum while deepening evidence for Nodify Lung, the company could help define standard-of-care pathways for the swelling lung nodule funnel. The strategic watch-out for 2026: who wins the race to become the default triage decision tool embedded in screening programs and EMR-driven care pathways—and how quickly payers codify that choice.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
